Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CACNA1G | O43497 | 1/20 | 0.36 |
| ▸ | CACNA1H | O95180 | 1/20 | 0.36 |
| ▸ | CACNA1I | Q9P0X4 | 1/20 | 0.36 |
| ▸ | HCRTR1 | O43613 | 2/20 | 0.36 |
| ▸ | HCRTR2 | O43614 | 2/20 | 0.36 |
| ▸ | AVPR2 | P30518 | 14/20 | 0.35 |
| ▸ | AVPR1A | P37288 | 5/20 | 0.35 |
| ▸ | POLB | P06746 | 1/20 | 0.35 |
| ▸ | SLC5A1 | P13866 | 1/20 | 0.35 |
| ▸ | OXTR | P30559 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14130337 | 0.94 | AVPR2 (0.39) | CACNA1GCACNA1HCACNA1IHCRTR1HCRTR2 | |
| SCHEMBL14130473 | 0.93 | CACNA1G (0.37) | CACNA1GCACNA1HCACNA1IHCRTR1HCRTR2 | |
| SCHEMBL14130166 | 0.92 | AVPR2 (0.37) | CACNA1GCACNA1HCACNA1IHCRTR1HCRTR2 | |
| SCHEMBL14130540 | 0.92 | CACNA1G (0.38) | CACNA1GCACNA1HCACNA1IAVPR2AVPR1A | |
| SCHEMBL14130199 | 0.90 | AVPR2 (0.38) | CACNA1GCACNA1HCACNA1IAVPR2AVPR1A | |
| SCHEMBL14130311 | 0.90 | LIPE (0.38) | CACNA1GCACNA1HCACNA1IHCRTR1HCRTR2 | |
| SCHEMBL14130472 | 0.90 | HCRTR1 (0.37) | CACNA1GCACNA1HCACNA1IHCRTR1HCRTR2 | |
| SCHEMBL14130073 | 0.90 | HCRTR1 (0.37) | CACNA1GCACNA1HCACNA1IHCRTR1HCRTR2 | |
| SCHEMBL14130443 | 0.88 | CACNA1G (0.42) | CACNA1GCACNA1HCACNA1IHCRTR1HCRTR2 | |
| SCHEMBL14130325 | 0.88 | CACNA1G (0.41) | CACNA1GCACNA1HCACNA1IHCRTR1HCRTR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080161294-A1 | Urea derivative, medicinal composition containing the same, and medicinal use of these | KISSEI PHARMACEUTICAL CO., LTD. (JP) | 2008-07-03 | — | — | US | disclosed |
| US-20080161294-A1 | Urea derivative, medicinal composition containing the same, and medicinal use of these | KISSEI PHARMACEUTICAL CO., LTD. (JP) | 2008-07-03 | — | — | US | disclosed |
| US-20080161294-A1 | Urea derivative, medicinal composition containing the same, and medicinal use of these | KISSEI PHARMACEUTICAL CO., LTD. (JP) | 2008-07-03 | — | — | US | disclosed |
| EP-1867639-A1 | UREA DERIVATIVE, MEDICINAL COMPOSITION CONTAINING THE SAME, AND MEDICINAL USE OF THESE | Kissei Pharmaceutical Co., Ltd. (JP) | 2007-12-19 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080161294-A1 | Urea derivative, medicinal composition containing the same, and medicinal use of these | AVPR2, UTS2R, GPR119 | CACNA1G 3324/4885CACNA1H 3214/4885CACNA1I 3150/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.